Physician profile
Mary E Gray
NPI 1184625055
$229.46
in general payments reported to CMS, 2019-2025
12 companies · $25.56 in 2025
The $25.56 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.96 · 2023: $97.12 · 2024: $68.82 · 2025: $25.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $191.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.11 | 2024 | Veozah |
| Abbvie INC. | $25.56 | 2025 | |
| Glaxosmithkline, LLC. | $23.20 | 2024 | Trelegy Ellipta |
| Amgen INC. | $22.90 | 2023 | Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $21.28 | 2022 | |
| Ucb, INC. | $19.63 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $16.68 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.08 | 2023 | |
| Exact Sciences Corporation | $13.69 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $13.51 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.05 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.